While the inhibitor of EZH2 (DZ-Nep) had no effect on pri-miR-22 expression at concentrations up to 10 μΜ uM (Supplementary Figure S2), a broad HDAC inhibitor, SAHA, used clinically for the treatment of CTCL, triggered a profound, time- and concentration- dependent up-regulation of pri-miR-22 expression (Figure 7). This evidence concerns the gene EZH2 and primary cutaneous T-cell non-Hodgkin lymphoma.